The S&P 500 dipped on Wednesday as a hotter-than-expected U.S. inflation reading added to worries that the Federal Reserve ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

U.S. consumer prices increased in January by the most in nearly a year and a half. The surge offered a cautionary note to Trump's push for tariffs.

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

U.S. stocks pared early losses on Wednesday but remained mostly lower after inflation data came in hotter than expected, potentially complicating the Federal Reserve's job of returning inflation to ...

We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...

Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...

Gilead Sciences has battled back from a pipeline disappointment last year to its highest stock price in nearly a decade.

Gilead Sciences reported its fourth-quarter financial results after Tuesday's closing bell. Here's a look at the highlights ...